ArticleCureus2025
Successful Treatment of Peripheral T-cell Lymphoma Not Otherwise Specified in Bilateral Subconjunctiva: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) typically presents in lymph nodes with advanced-stage disease. Ocular adnexal involvement, particularly bilateral subconjunctival presentation, is exceptionally rare. We describe a 39-year-old woman who presented with progressive bilateral conjunctival masses despite one year of topical corticosteroid treatment. Examination revealed well-demarcated pink subconjunctival nodules in both eyes. Following surgical excision, histopathological and immunophenotypic analyses confirmed PTCL-NOS with CD3+/CD4+ T-cell infiltration. Molecular studies detected clonal T-cell receptor gene rearrangement in both tumor tissue and bone marrow, indicating stage II disease. The patient achieved complete remission with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy and remains disease-free after three years. To our knowledge, this represents the first reported case of primary bilateral subconjunctival PTCL-NOS successfully managed with systemic chemotherapy, highlighting the importance of comprehensive evaluation and aggressive treatment in this unusual presentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.